Vistagen Therapeutics Stock Price History
| VTGN Stock | USD 2.79 0.02 0.72% |
Below is the normalized historical share price chart for VistaGen Therapeutics extending back to June 21, 2011. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of VistaGen Therapeutics stands at 2.79, as last reported on the 22nd of March, with the highest price reaching 2.81 and the lowest price hitting 2.73 during the day.
If you're considering investing in VistaGen Stock, it is important to understand the factors that can impact its price. VistaGen Therapeutics appears to be very risky, given 3 months investment horizon. VistaGen Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0555, which indicates the firm had a 0.0555 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for VistaGen Therapeutics, which you can use to evaluate the volatility of the company. Please review VistaGen Therapeutics' Coefficient Of Variation of 1599.53, semi deviation of 2.79, and Risk Adjusted Performance of 0.0631 to confirm if our risk estimates are consistent with your expectations.
At this time, VistaGen Therapeutics' Issuance Of Capital Stock is very stable compared to the past year. As of the 22nd of March 2025, Stock Based Compensation To Revenue is likely to grow to 2.48, while Common Stock Shares Outstanding is likely to drop about 11.6 M. . As of the 22nd of March 2025, Price Earnings To Growth Ratio is likely to grow to 56.54, while Price To Sales Ratio is likely to drop 56.52. VistaGen Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 6th of May 2016 | 200 Day MA 3.0856 | 50 Day MA 2.8224 | Beta 0.618 |
VistaGen |
Sharpe Ratio = 0.0555
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VTGN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.59 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.2 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average VistaGen Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of VistaGen Therapeutics by adding it to a well-diversified portfolio.
Price Book 0.9855 | Enterprise Value Ebitda (0.19) | Price Sales 114.5387 | Shares Float 20.2 M | Wall Street Target Price 13 |
VistaGen Therapeutics Stock Price History Chart
There are several ways to analyze VistaGen Stock price data. The simplest method is using a basic VistaGen candlestick price chart, which shows VistaGen Therapeutics price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | January 3, 2025 | 3.34 |
| Lowest Price | March 3, 2025 | 2.49 |
VistaGen Therapeutics March 22, 2025 Stock Price Synopsis
Various analyses of VistaGen Therapeutics' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell VistaGen Stock. It can be used to describe the percentage change in the price of VistaGen Therapeutics from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of VistaGen Stock.| VistaGen Therapeutics Accumulation Distribution | 2,182 | |
| VistaGen Therapeutics Price Rate Of Daily Change | 1.01 | |
| VistaGen Therapeutics Price Daily Balance Of Power | 0.25 | |
| VistaGen Therapeutics Price Action Indicator | 0.03 |
VistaGen Therapeutics March 22, 2025 Stock Price Analysis
VistaGen Stock Price History Data
The price series of VistaGen Therapeutics for the period between Sun, Dec 22, 2024 and Sat, Mar 22, 2025 has a statistical range of 1.09 with a coefficient of variation of 7.67. The daily prices for the period are distributed with arithmetic mean of 2.79. The median price for the last 90 days is 2.81. The company experienced 1:30 stock split on 7th of June 2023.| Open | High | Low | Close | Volume | ||
| 03/21/2025 | 2.77 | 2.81 | 2.73 | 2.79 | 76,653 | |
| 03/20/2025 | 2.75 | 2.84 | 2.63 | 2.77 | 206,450 | |
| 03/19/2025 | 2.71 | 2.78 | 2.61 | 2.72 | 106,665 | |
| 03/18/2025 | 2.81 | 2.85 | 2.69 | 2.70 | 112,769 | |
| 03/17/2025 | 2.73 | 2.86 | 2.68 | 2.82 | 140,920 | |
| 03/14/2025 | 2.75 | 2.77 | 2.63 | 2.70 | 125,227 | |
| 03/13/2025 | 2.80 | 2.81 | 2.66 | 2.72 | 51,873 | |
| 03/12/2025 | 2.73 | 2.83 | 2.72 | 2.79 | 44,604 | |
| 03/11/2025 | 2.63 | 2.77 | 2.59 | 2.72 | 72,433 | |
| 03/10/2025 | 2.67 | 2.83 | 2.64 | 2.66 | 121,642 | |
| 03/07/2025 | 2.67 | 2.83 | 2.62 | 2.76 | 171,215 | |
| 03/06/2025 | 2.65 | 2.69 | 2.56 | 2.67 | 141,100 | |
| 03/05/2025 | 2.67 | 2.71 | 2.61 | 2.70 | 101,340 | |
| 03/04/2025 | 2.45 | 2.67 | 2.35 | 2.65 | 264,187 | |
| 03/03/2025 | 2.65 | 2.68 | 2.49 | 2.49 | 127,685 | |
| 02/28/2025 | 2.54 | 2.73 | 2.51 | 2.70 | 128,473 | |
| 02/27/2025 | 2.65 | 2.68 | 2.53 | 2.54 | 125,056 | |
| 02/26/2025 | 2.62 | 2.78 | 2.59 | 2.61 | 94,000 | |
| 02/25/2025 | 2.72 | 2.80 | 2.61 | 2.62 | 238,036 | |
| 02/24/2025 | 2.99 | 2.99 | 2.71 | 2.72 | 199,160 | |
| 02/21/2025 | 2.88 | 2.99 | 2.81 | 2.93 | 279,600 | |
| 02/20/2025 | 2.90 | 2.90 | 2.72 | 2.87 | 181,988 | |
| 02/19/2025 | 2.96 | 3.01 | 2.83 | 2.85 | 160,329 | |
| 02/18/2025 | 2.95 | 3.02 | 2.87 | 2.94 | 190,000 | |
| 02/14/2025 | 2.95 | 3.10 | 2.78 | 2.97 | 265,700 | |
| 02/13/2025 | 2.77 | 2.87 | 2.73 | 2.85 | 192,000 | |
| 02/12/2025 | 2.61 | 2.77 | 2.61 | 2.74 | 96,157 | |
| 02/11/2025 | 2.77 | 2.81 | 2.60 | 2.70 | 118,639 | |
| 02/10/2025 | 2.83 | 2.87 | 2.70 | 2.76 | 287,700 | |
| 02/07/2025 | 2.87 | 2.88 | 2.71 | 2.81 | 214,174 | |
| 02/06/2025 | 3.00 | 3.02 | 2.84 | 2.87 | 180,196 | |
| 02/05/2025 | 2.84 | 3.02 | 2.84 | 2.95 | 582,600 | |
| 02/04/2025 | 2.90 | 3.04 | 2.83 | 2.86 | 168,700 | |
| 02/03/2025 | 2.84 | 3.01 | 2.81 | 2.91 | 216,800 | |
| 01/31/2025 | 2.96 | 3.08 | 2.83 | 2.89 | 218,500 | |
| 01/30/2025 | 2.87 | 3.02 | 2.79 | 2.94 | 111,700 | |
| 01/29/2025 | 2.84 | 2.88 | 2.77 | 2.86 | 82,600 | |
| 01/28/2025 | 2.87 | 2.92 | 2.80 | 2.86 | 91,300 | |
| 01/27/2025 | 2.94 | 2.94 | 2.82 | 2.88 | 108,700 | |
| 01/24/2025 | 2.95 | 2.98 | 2.88 | 2.95 | 87,100 | |
| 01/23/2025 | 2.99 | 3.01 | 2.89 | 2.97 | 110,500 | |
| 01/22/2025 | 3.01 | 3.07 | 2.93 | 2.99 | 131,800 | |
| 01/21/2025 | 2.95 | 3.05 | 2.90 | 3.01 | 214,700 | |
| 01/17/2025 | 2.92 | 3.10 | 2.85 | 2.92 | 108,700 | |
| 01/16/2025 | 2.98 | 3.04 | 2.89 | 2.92 | 123,100 | |
| 01/15/2025 | 2.91 | 2.97 | 2.83 | 2.97 | 259,300 | |
| 01/14/2025 | 2.93 | 2.96 | 2.83 | 2.84 | 342,700 | |
| 01/13/2025 | 2.96 | 2.98 | 2.85 | 2.93 | 164,900 | |
| 01/10/2025 | 3.03 | 3.05 | 2.89 | 2.97 | 177,000 | |
| 01/08/2025 | 3.19 | 3.23 | 2.93 | 3.03 | 300,700 | |
| 01/07/2025 | 3.22 | 3.35 | 3.09 | 3.12 | 193,800 | |
| 01/06/2025 | 3.30 | 3.37 | 3.18 | 3.20 | 296,800 | |
| 01/03/2025 | 3.36 | 3.40 | 3.15 | 3.34 | 497,900 | |
| 01/02/2025 | 3.00 | 3.34 | 2.97 | 3.32 | 702,700 | |
| 12/31/2024 | 2.85 | 2.99 | 2.83 | 2.95 | 353,600 | |
| 12/30/2024 | 2.55 | 2.83 | 2.52 | 2.81 | 377,700 | |
| 12/27/2024 | 2.59 | 2.69 | 2.48 | 2.57 | 430,200 | |
| 12/26/2024 | 2.52 | 2.61 | 2.40 | 2.60 | 614,900 | |
| 12/24/2024 | 2.55 | 2.63 | 2.45 | 2.55 | 293,000 | |
| 12/23/2024 | 2.44 | 2.63 | 2.43 | 2.57 | 676,800 | |
| 12/20/2024 | 2.25 | 2.55 | 2.23 | 2.50 | 993,000 |
About VistaGen Therapeutics Stock history
VistaGen Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for VistaGen is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in VistaGen Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing VistaGen Therapeutics stock prices may prove useful in developing a viable investing in VistaGen Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 17.4 M | 11.6 M | |
| Net Loss | -53.3 M | -50.7 M |
VistaGen Therapeutics Stock Technical Analysis
VistaGen Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
VistaGen Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for VistaGen Therapeutics' price direction in advance. Along with the technical and fundamental analysis of VistaGen Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of VistaGen to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0631 | |||
| Jensen Alpha | 0.2744 | |||
| Total Risk Alpha | 0.5353 | |||
| Sortino Ratio | 0.1013 | |||
| Treynor Ratio | 0.3436 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share | Quarterly Revenue Growth (0.43) | Return On Assets | Return On Equity |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.